Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Deals Generic Drugs

Fresenius Kabi To Build ‘One Of The Largest Sterile Injectable Manufacturing Networks In US’

Alliance With Phlow Will Strengthen American Resilience To Public Health Crises

  • Interviews

Executive Summary

Stating the importance of the US sterile injectables market for Fresenius Kabi, Matt Kuhn, senior director of external communications, talks to Generics Bulletin about the company’s plans to build one of the largest sterile injectable manufacturing networks in America. Meanwhile Ali Ahmed, senior vice president of biosimilars at Fresenius Kabi in the US, talks about supply reliability in biosimilars. 

Table

View full table

Topics

Related Companies

Tags:
Biosimilars Deals Generic Drugs
Latest Headlines

Biocon And Biomm Team Up In Brazil On Ozempic Rival – With Potential Near-Term Launch

Amneal Launches Ready-To-Use Pemetrexed And OTC Naloxone

…And Amgen Makes Three: Another Ustekinumab Biosimilar Gets Go-Ahead In EU

No Takers For Biogen’s Biosimilars Business?

See All
UsernamePublicRestriction

Register

GB151419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By